Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2019-12-13 Regulatory Filings
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA – With support from Bristol-Myers Squibb and Ultimovacs, UV1 will be tested in a large, randomized combination trial in mesothelioma initiated by Oslo University Hospital
Regulatory Filings Classification · 95% confidence The document is an announcement from Ultimovacs ASA, dated December 13, 2019, detailing the initiation of a new clinical trial (NIPU) for their cancer vaccine UV1 in combination with other drugs for mesothelioma treatment. It describes the trial design, patient numbers, expected timelines (PFS read-out mid-2022), and includes quotes from the CEO and principal investigator. This content is characteristic of a press release or news update regarding clinical development progress, which typically falls under general regulatory announcements or investor relations updates, but does not fit the specific definitions for 10-K, IR, ER, or MDA. Since it is a specific announcement about clinical trial progress and partnership support, and not a general regulatory filing fallback (RNS), it is best classified as an Investor Presentation (IP) if it were a deck, or more generally, a Regulatory Filing (RNS) as it is a formal company announcement of material information not covered by other specific codes. Given the options, and that it is a formal announcement of material corporate/clinical development news, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, although it shares characteristics with an Investor Presentation (IP) if it were a slide deck. Since it reads like a press release, RNS is the safest general classification for material, non-financial periodic news.
2019-12-13 English
Ultimovacs ASA – Poster presentation at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Regulatory Filings Classification · 99% confidence The document is a short announcement from Ultimovacs ASA stating that results from a clinical study (UV1 in malignant melanoma) will be presented as a 'Poster presentation' at the '2020 ASCO-SITC Clinical Immuno-Oncology Symposium'. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER) or management discussion (MDA). It is an announcement about the presentation of scientific/clinical data at an external industry event. Since there is no specific category for 'Clinical Presentation Announcement', and it is an announcement regarding the presentation of company data/research, it best fits under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, or potentially Investor Presentation (IP) if the poster itself was the primary focus, but since this is an announcement *about* the presentation, RNS is the most appropriate fallback for non-standard corporate news.
2019-12-04 English
Ultimovacs ASA: Third quarter 2019 result presentation
Interim / Quarterly Report Classification · 100% confidence The document is titled 'THIRD QUARTER 2019 REPORT' and contains comprehensive financial statements (Q3-19, YTD-19), operational highlights, CEO commentary, and clinical trial updates. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2019
2019-11-14 English
Ultimovacs ASA: Third quarter 2019 result presentation
Investor Presentation Classification · 98% confidence The document is explicitly titled 'Third quarter 2019 presentation' and dated '14 November 2019'. It contains detailed clinical trial updates, financial tables comparing Q3-19 to Q3-18 and YTD figures, and a CEO/CFO sign-off. This structure is characteristic of an Investor Presentation (IP) or a presentation accompanying an Earnings Release (ER). Since it is a 'presentation' format, detailing strategy, clinical progress, and key financials for a specific period (Q3 2019), the most appropriate classification is Investor Presentation (IP). It is not the full, formal regulatory report (like 10-K or IR), nor is it just the initial press release (ER), but a detailed slide deck for investors.
2019-11-14 English
Ultimovacs ASA: Third quarter 2019 result presentation
Report Publication Announcement Classification · 99% confidence The document is titled 'Ultimovacs ASA: Third quarter 2019 result presentation' and explicitly announces the 'third quarter 2019 results' along with a presentation schedule. This indicates it is an announcement of periodic financial results, which aligns with the Earnings Release (ER) definition. Although it contains some operational highlights, the primary purpose is the release of period results. Since the document is short (2789 chars) and focuses on announcing the results and presentation, it is classified as an Earnings Release (ER) rather than a comprehensive Interim Report (IR) or a mere Report Publication Announcement (RPA), as it contains the key highlights of the results themselves.
2019-11-14 English
Ultimovacs ASA – LONG TERM RESULTS FROM UV1 CLINICAL STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Earnings Release Classification · 99% confidence The document is a press release from Ultimovacs ASA announcing 'LONG TERM RESULTS FROM UV1 CLINICAL STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER' presented at a conference (SITC 2019). It summarizes key clinical findings (safety, immune response, survival rates) and mentions that detailed results are available via a poster and on the company website. Since this is an announcement summarizing results from a clinical trial/study, and it is not a comprehensive annual report (10-K), a formal interim report (IR), or a general earnings release (ER), it best fits the category for general regulatory/investor information that isn't covered by the more specific codes. Given the options, this type of announcement, which is essentially a scientific/clinical update shared with investors and the public, most closely aligns with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but since it's a press release detailing study outcomes, RNS serves as the best general fit for non-standard, material updates that aren't formal financial reports or specific management changes. However, since it is a detailed update on clinical progress, it is a significant piece of investor information. Given the options, and the fact that it is a press release announcing study data, it is not a formal financial report. It is a material update. RNS is the fallback, but let's re-evaluate against other options. It is not an IP (Investor Presentation) as it's a text release, not a presentation deck. It is not an ER (Earnings Release) as it focuses on clinical data, not quarterly financials. Therefore, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of material clinical update announcement. Q4 2019
2019-11-09 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.